Search results
Results from the WOW.Com Content Network
Although both vasopressors, vasopressin and epinephrine differ in that vasopressin does not have direct effects on cardiac contractility as epinephrine does. [18] Thus, vasopressin is theorized to be of increased benefit over epinephrine in cardiac arrest due to its properties of not increasing myocardial and cerebral oxygen demands. [18]
Cardiac arrest (also known as sudden cardiac arrest [SCA] [11]) is when the heart suddenly and unexpectedly stops beating. [ 12 ] [ 1 ] When the heart stops beating, blood cannot properly circulate around the body and the blood flow to the brain and other organs is decreased.
551 11998 Ensembl ENSG00000101200 ENSMUSG00000037727 UniProt P01185 P35455 RefSeq (mRNA) NM_000490 NM_009732 RefSeq (protein) NP_000481 NP_033862 Location (UCSC) Chr 20: 3.08 – 3.08 Mb Chr 2: 130.42 – 130.42 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized ...
Unlike cardiac arrest, a heart attack is a circulation problem. When circulation is blocked or cut off in some way and blood is no longer supplied to the heart muscle, this can damage that muscle ...
Research has made clear how linked mental and cardiac health really are. A new study suggests women might experience the association differently post-cardiac arrest.
Vasopressin comes as the second-line agent. [24] However, high-dose therapy is linked to excessive coronary, splanchnic vasoconstriction, and hypercoagulation. [6] Excessive vasoconstriction can cause cardiac output reduction or even fatal heart complication particularly in those with weak myocardial function. [6] [4] [28] [29]
For example, white men who experienced cardiac arrest and received CPR from a bystander were 41% more likely to survive, the best odds of any group. Meanwhile, Black women had the lowest survival ...
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.